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A recent malaria ep idemic in th e M cn oreh Hills of Ce ntral j ava has increa sed co nce rn abo ut the re-e me rgence
of endemic m alaria on j ava, whic h th rea ten s the islan d 's 120 million res ide n ts. A 2R-uay, in-vivo test of the
efficacy oftreat me nt of malariu with ant irnalnrial drugs was con du cted amo ng 167 village rs in the .\ \c no reh Hills.
1111." treatment s investiga ted . chloroq uine (e Q) and sulfa do xine- pyrimc thum ine (SP) , co nstit ute, respectively, th e
first- and seco nd -line rrcarmcn rs for uncomplicated malaria in Indonesia. 'I111~ prevalenc e of malaria among 1389
resi dents screened prior to enroll men t was 3.l% . Treatm en t o utc o mes were assessed by micros copical di agn oses,
p eR-based confi rmation of the di agn oses, me asu reme nt or the whole -blo od co nce nt rations of C Q and descth ylchloroq uine (DC Q) , an d ide ntifica tion of the Plasmodium [alc iparunt genoty pes. The 2 8 ~<b y cumulative incidences
of the ra pe utic failure fo r C Q and SP we re, respec tively, ·17')1" ( N= 36) an d 22% (N = ; 0) in the treat ment of
P. jalcipimt1l/, and 18'1.. ( 0\'= 7 7) and 67 % ( X= 6) in the treatm ent o f P, 1'h."1.\:. Chloroquine was thus an
ineffective therapy for P. [alciparurn malaria, an d the pr esen ce of C Q- rcsistant P. V i1!aX and SP-rcs istant
P. j akip," "/tIIl will further co mprom ise efforts to co ntrol resurgen t miliaria on j ava.

Java, which lies between Sum atra and Bali,
is the m ost heavily populated island in the
Indonesian archipelago . Wide-spr ead hyp erand hole-endemic m al ari a occ urr ed o n Java
(Swellengrebcl et al. , 19 19; Schuurman an d
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Schuurman-Tcn Bokkel Huinink, 1929) until
the 1950s. A m alari a-erad icat ion ca mpaign
dominat ed by DDT sp ra ying was th en
successful in th e E ast an d West p rov inces
of Java and brought m alari a transmission
under co n tr ol in the C en tra l provin ce
(Atm osocd jono, 19 94) . H owever, the cam paign did n ot elim ina te thc speci es of
m osquito that had transmi tt ed th e m alari al
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pa ras ites. H abitat s tha t suppo rt notorio us
vect or s suc h as A nopheles sundaicus, An.
maculatus, A ll. balabaceusis and Au. aconitus
still d ominate the landscape, and j ava rem ains
high ly receptive to end em ic m alari a.
The malaria situati on on Java re mained
stab le from 1960 to about lCJ97. However ,
th e tumultuous political, soc ial and econo mic events that have occurred in Indonesia
ove r the past 5 years and th e Asian eco nomic
crisis of 199 7 devas ta ted b udgets for m alar ia
co n tro l. During thi s time, th e inci dence
of ma laria o n Java has risen m ar kedl y.
Altho ugh ra re befo re 199 7, outbreaks
invo lving th ousands of people now occur
regu larly. T he an n ual pa rasi te inci de nce
for Java inc reased 8-fo ld, from 0. 1 to 0.8
infec tio ns/ 1000 person-years, between 1996
and 2000 (Barcus et al. , 2002).
A recent m alari a epidem ic in th e M en or eh
Hill s of Cen tra l Java was investigated by
Bar cu s et al. (20 02) . In th e mo st badl y
affec ted area} th e district of Pu rwo rcio, th e
an nua l para site inciden ce incre ased from five
[Q 48 infec tions/ IOOO pe rson-years between
1997 and 2000. The s tra tegy for attacking
th is ongoing epidem ic includes plans for
mass ant ima larial drug administration (M D A)
in specific, high-risk areas. As it was u nclear
how effec tive th e available ant imalarial
drugs were likely to be, the p resen t clinical
eva luation of two therapies for th e trea tme nt
o f un complicated, P, [alcipurum and P. vivax
malari a in Purwor ejo was cond uc ted .

SUBJECTS AND M ETHODS
S t u dy Location

T he stu dy was ba sed in Purworei o district,
which lies at 07 43 '- 0 7' 46 'S and 110 05 '110 OTE, in th e Central province of Java
(Fig.). The district has a population of approxirnately 750,000, m ost of who m are engaged
in agricu ltu re. Three hab itats characterize
th e landscape: ( I) a narrow coastal strip of
ma ngrove and swa m p, wit h fish po nds ; (2) a
broad plain d ominat ed by rice pa ddies; and
(3) th e fore ste d and cu ltivated hills (F ig.).

The abundant rainfall (4000 rum/year) and
yea r-ro u nd tem peratures ra ngi ng from
2 3-36 C create a warm and hu mid, tropi cal
climate. M ost h uman ma laria occ u rs in the
hills, where th e vectors A ll. mac ulatus and
A n, balabacensis breed in sha dy seepage pools
or rocky strea m beds (Ta kken and Kn ols,
1990) , Us ing d at a colle cted at government operated clinics as the res ult of passive
malaria surveillance, four villages in th e dis trict were ide ntified as high-risk commu nities
for malaria: Kaliharjo, Loano, N garan and
Ka ligono. Each of the se villages is loca ted
on steep hillsides in the cast of the di strict,
at 160 - 780 m above sea level.

Stu dy S u bjects an d E n ro llme nt

Potential subjects were identified du rin g
mass scree nings conducted, in the fou r hig hrisk villages, at the req uest of local he alth
authoriti es. Overall, 1389 residents (7% of the
co mb ined po pulat ion) p rese n ted for screening and provided fingerprick-blood samples
for the preparat ion of Gic msa-srainc d bloo d smears. After the sm ears were checked for
malarial pa rasites by mic ro scopical examination, all of those with slide-confirmed
malaria were offered standard antima larial
the rapy. Those who were aged ~ 5 years
and thick-smear-positive for asexual parasites ( > 40 asexual parasites/ul ) were invited
to en rol in the pre sent study, afte r provid ing
informed co nsent. The study protocol and
informed-consent p rocedu res co nformed to
the reg ula tions of th e Repub lic o f Ind onesia
and U.S, N avy govern ing th e use of h uman
subjects in med ical research and were reviewed
and approved by all convening inst itutiona l
review boards. A full clinica l assess ment,
including medical histo ry, physica l exa mina tion and basic laboratory testing, was
completed to de termine eligibility. Excl usion
criteria included complicated malaria (W H O ,
2000), a history of antimalarial the rapy in
the past week, history of allergy or adverse
reac tion to chloroquine (C Q) or sulfadoxine-pyrimcthaminc (SP) , pregnancy, or
unwi llingness to participate.
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FIG. Map of Java showing the loc ation of Pu rwore]o district. Th e inset shows the district in more de tail. with
the locutions of the four study villages and the sub-districts in which hills (.), low paddy ( ) and coastal plains
( ::J) form the predominant feature of the terrain.

In-vivo Test
Assignment to the vario us treatment arms
was based o n the resul ts of th e microscopical
di agn oses and th e locall y applied th erapeutic
practice s. Although Loa no village followed
the guideli nes of the Indonesian Mini stry of
H ealth (IM o H) , in usin g C Q as first-line
therapy for uncomplicated, P. [a lciparum
m alaria, the other three study villages had
ind epe nde n tly ado pted SP as the first- line
treatm ent. The treatm ent groups were therefore: ( I) C Q for P. falc iparum o r mixed
P. oioaxlP. [alcipannn in Lo an o; (2) C Q for
P. oiuax in all villages; (3) SP for P, fa kipannn
in all villages exce pt L oan o; and (4) SP for

mixed P. uiuaxtl", falcipan un in all village s
except Loan o.
Subje cts in the two C Q-trcatmc nt groups
received directly ob served doses of chlo roquine dipho sphate (Resochin t~; 150 rng base;
P . T . Bayer Ind onesia, Jakarta): 10 mg base/kg
on d ay 0, 10 mg base/kg on da y I , an d 5 m g
base/kg on da y 2. Subject s in th e two SPtreatment groups received Fan sidar" tablets
(500 mg sulfado xine/2 5 mg pyrimethamine;
Hollman La Roche Ind onesia, Jakarta) as a
single d ose (the tablets being broken int o
quarters so that a do se of abo ut 25 mg sulfad oxine and 1.25 mg pyrim etha m ine/kg co uld
be given ), Although the IM o H ' s guid eline s
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advoc ate a single do se uf <15 mg primaqu ine
base for P. [alciparum; as a transmission blocking mea sure, and five daily doses o f
primaquine base ( 15 rug /day) against P. vnsax
relapse , primaquine tre atment was deferred
until the st ud y endpoint. [As primaquine
has ap p reciable blood sc h izonticida l activiry
against P. viuax (Pu kri ttayakarnee ct at.,
19 9-1), its use would have made it difficult
to gauge the therapeutic efficacy of CQ
against P. vivax.]
Su bjects were ac tive ly foll ow ed for 28
days, with bJoodsme ars being made on days
0, 1, 2, 3 ,4, 7 , 11, l-l , 18 , 21 and 28 and
o n any day a subject com plained of illness .
Blood-blot spe cimens were obtained , for
estimation of whole-blood co nce ntrations
of C Q an d de sethylchloroquine (OC Q) by
HPLC, on da y a ( p re-t rea tment ), d ay 2 an d
eithe r day 28 or the day of recurrent parasitaernia. Blood-blots for DNA analysis were
collected on days 0, 7, 14, 21 and eith er 2R
or the day of recurrent parasit aemia . All the
samples for the blots were collected from
fingerpricks into heparinized, 1OO-~II microca pillary tubes and exp elled on to Whatm""
1':0. I filtcr paper (W h atma n International,
M aid stone, U.K.) for dryin g and sto rage.
S ubjects with persistent or rec urren t parasitae rnia during foll ow-up were treated,
accord ing to the I~\oH ~s guide lines, with SP
(for P. falciparum after failure ofCQ th erapy)
or qu inine (e ither for P. [alciparnm after
failure o f SP th erap y or for second-line
treatm ent of P. 1.'i~:ax ) .

Laboratory

~\ethods

," ICROSCOPY

Bloodsm cars were examined by exp ertce rtified microscopi sts. A thick smear was
only declared neg ative if one or no asex ualsta ge parasites h ad been seen aft er 200 fields
of th e smear had be en checked at x 1000.
A positive readi ng required at least two
unambi guous asex ual parasites in 200 fields .
Asexu al parasites were counted against 200
leucocytes in th e thick smear and the counts
co nve rted to parasites /ttl, assuming each
subject had 8000 leucocytes/ul.

OETF.CTIN"G J!':FECT IOSS USING peR
'Ibe single-stranded ribosomal R.'1A (ssrRN A)
of any malarial parasites present in a dried
blood-blot was am plified by PCR, both to
cunfinn the microscop ical diagnoses and to
detect any microscopically sub parcn t parasita ernias. DNA was extracted directly from
the blot s of blood co llec ted on da y a and
day 28 or [he day of recurrent purasitaernia,
usin g C helcx'" 100 5 f}:, resin (Bio-Ra d
La b uruto ries, H ercules, CA) in d istille d
water. Samples were incub at ed for 20 m in
in a h eat block at 56 C, followed by 8 mi n
in a heat bloc k at 100 C. T he speciesspecific variant do mains of the malarial
ssrRJ"J'A genes were then amplified (Kimura
ct al. 199 7) . \X'h en the results of the micro scopical and PeR-based diagnoses were disco rdant, two microscopists who were blinded
to the result of the PC R-based diagnosis
re-exa mined the relevant smear. The final
res u lt was taken to be that of the PCR and
at least one microscopist or, whe n they concurred, [hat of both microscopists (even if
this co nflicted with the PCR result) .

~CREEr-;I~(j

Pregnan cy was assessed by the semiq uantitative measurement of urinary hum an
cho rionic gonad otropin , using a comme rcial
kit (Urin e h CG Test Pack Plus; Abbott
Labora to ries, Abb ott Par k. IL). Haemo globin levels were determined for all of the
study subjec ts, in a Lei ca Hb-Mctcr (Lc ica,
Buffalo , NY).

GF.~On~PJKr.

T he blots of blood co llected from those
infected with P. falcipannn who had recurrent parasitaemia were used to disting uish
recrudescences from re-infection s. 111e parasites in the blots of the blood sam ples
co llec ted on day 0 and [he day of the recurrent parasitaem ia were gcno rypcd on the

CQ OR SP
basis of their me rozoite su rface protcin-Z
('\ \ SP-2) gene' (F elger , I al. , 1993).
HPLC Al':ALYSES
Blots of bloo d ( 100 pi ) co llec ted on da y 0,
d ay 2, and da y 28 or the da y of recurrent
par asit uem ia were used [ 0 d eterm ine th e
w ho le- bloo d co nce n trat io ns of CQ and
D CQ by I-lPLC (.\ l od e! 2700; Bio- Rad,
Ric h mon d, CAl . HPLC was also used to
determine the sul fadoxinc and p~vrirn ctharnine
concent ratio ns in the pla sm a fro m bl ood
sam ples collected on the d ays of rec urr en t
parasiracrnia (Ed stein ,I al., 19 9 1) ; th e
lower limits of th ese qua nt ifications were
100 ng.rnl for sulfad oxine and 5 ng/ml for
pyrimethamine.
Data A n a lysis
T he m ain aim of th e presen t stu dy was to
estima te th e risk of therap eutic failu re after
su pe rvise d trea tment with sta nd ard an tim alari als - specifically, [0 es tim ate th e
risk of th er apeutic failu re whe n treating
P. [ alcipa rum o r P. Vi7XIX w ith C Q and whe n
treati ng P. [alcipannn with SP. S ubi ects with
both recurren t pa rasit acmia and day-Z CQ +
DCQ blood concentrations of < 305 ng /rnl
( i.c. more than 1 S. D. below the me an for the
study population) were excluded (C Q + D CQ
concent rations be low this threshold we re co nsid ered consistent with inadequate absorption,
since compliance was ens ur ed ) . Subjects
who cleared the ir parasita cm ias b ur had
C Q + n CQ concen tra tions co ns iste nt with
ina de qua te abso rption were not exclude d
because) in these cases, C Q sens itivity wa s
established by cl inica l cure d espite th e d rug
conce n tratio ns. S ubjects lost to follow -u p o r
withdrawn because they were trea te d for
intercurrent infection (w it h a Plasmodium
species other than the one presen t on day 0)
befo re the end of the follow-up period co ntributed to the person-time at risk up to th e
point of th eir loss /withdrawal. Subjects with
mismatch ed ~\ l S P 2 genotypes at enrollme nt
and recurrence were classified as rc- infccted
and treat ed ana lytically as wi th d ra w.a ls.

r on
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Subject s wh o d eveloped recurrent P. t'WtlX
whil e they had C Q + D CQ co ncent ra tions
of < 100 ng/m l were also co u n ted as withdrawals, because their recu rrent purasitacmias
co u ld have been th e result o f relapse or
re-i nfection. The rati onale for in terp reting
the resul ts of th e in-vivo tests for C Q agai nst
1'. viuo» is d erail ed elsew here (Baird el £II.,
1997 a). C um ulative inci d ence, o r risk, o f
therap eutic failure was estim at ed by act ua rial
( life-table) ana lysis.
RES ULTS
Screening
Among 1389 villagers screened, -l52 (33%)
had slide-confirmed malaria. T he village
p reva lence o f ma larial in fec tio n ra nged
from 26'}{, to 38 % . O ver all, 37 %, 57 % and
6'% of the in fec tio ns d ete cted were pure
1'. [a lcipurnm, p ure P. viuax and m ixed
P. [alcipanuulP. vioax, respectively. Am o ng
th e 4 52 pa rasitaernics, 173 (38% ) co mp lain cd of illness co ns iste nt with malaria.
Demographic, Clinical and
Parasitological Parameters at
E n ro llmen t
Ove rall, 167 su bjects were enrolled in
the treatmen t trial: 73 with pure P. '('; '(hIX
infections, 7 --l with p u re P. fakiparum,
an d 20 with m ixed P. [alcipartnnlP, cicux
infec tions . Table I lists the d emograph ic,
clinical and pa ras ito log ica l cha racteris tics of
th e su bjects b y treatm ent group . The rati o
of female to ma le subjects was 1.3: I . The
preva lence o f sp leno megaly was consistent
w ith h ype r-e nd emic m alaria . Splenomegaly
was observed in most of the ad ults and all
of the childre n enrolled, alt hough o nly 13
su bjects we re aged < 10 years. Of the 9-i
subjects infected with P. [alciparum (in
p ure or mixed infections), 3 1 (33 1Y..) were
feb rile and 60 ( M%) were symptomatic
(with headache, ma laise) myalgia. arthra lgia ,
abdominal pain, fever and /or chi lls) . Of the
93 subjects with P. uirax ( in pure or mixed
infect ion s) , 15 (16 %1) \\'CT~ feb rile an d 45
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(4 8%) co m plained of symptoms. In ge neral,
the P. [ alciparum parasite densities were
greater than th ose of P. vivax; the o nly
excep tion was in the mixed infection s in
those treated with CQ , w he re the P. viuax
parasite densities were g reater than the
P. fal ciparum .

Drug C o n ce n trati o ns
Table 2 su m m arizes the CQ + D C Q co ncentrations in the blood samples collected ,
from the subjects treated with CQ, on day
o ( pre-treatm ent) , da y 2 and the day of
recurrent para sitaernia. •Mixed infections are
included in bo th the P. falciparum and
P. ,(liv ax co lumns. Pre-treatment samples were
avai lab le for 38 and day-2 sa mples for 37 of
the 40 sub jects in fected with P. falciparum
and treated with CQ. Pre-treatment and
day-2 samples were available fo r 76 and
75, respectively, of the 87 indi viduals
with P. v ivax who we re treated with CQ .
CQ + DCQ co ncentrations we re dete rmined for all 44 subjects w ith rec urrent par asitaernia during follow-up. Among those
tre ated with CQ, 4 2% ( 16/38) of the subjects with P. fatcipanon and 37 % (28176) of
those with P. oicax had d etectable C Q +
DCQ co ncentratio ns prior to enrollment,
indicating self-ad m inistered CQ. The ove ra ll
me an (s.n.) day-2 CQ + D CQ co ncentration
for all those treated with C Q (regard less
o f parasit e species) was 667 (36 2) ngim l.
Although two of th e sub jects infect ed with
P. [u lcipannn and five of those infected with
P. uiuax had day-2 concentrations far bel ow
norma l, only one of these seve n subjects
(who had a P. vivax infection) developed a
recurrent parasita ernia and was there fore
excluded from the estima tio n of therapeutic
efficacy, o n the presumption of inadequate
C Q ab sorption.
Am ong th e 54 su bjects treated for
1'. [a lcipannn with SP, only 22 da y-O ( pretreatment ) plasma samples \v·ere available
for measurement o f sulfad oxine and pyrimethamine concentrations. Six (2 70/0) of
these 22 had det ectable sulfadoxine and
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pyrimethamine co nce ntrations, indica ting
recent use of SP prior to enrollment. Plasma
samp les from th e day of rec urrent parasitacrnia we re available from six of the nine
subjects who experienced SP therapeutic
failu re (T able 3) . With th e except ion o f o ne
subject with und etectable pyrimethamine
co nce ntrations, all six subjects had d etectab le concentrations of bo th drugs on the day
of recu rren ce, with mean co ncen tratio ns of
28 ug sulfad oxine and 48 ng pyrimethamine/
ml, respectively .
Post-therapeutic C li n ic a l Course of
P. fa lciparurn Malaria
Clinical co urse did nor differ between treatment groups. M ost of th e physical complai nts reported at enrollme nt had resolved
by d ay 4 , whether those affected had been
treat ed with C Q o r SP. The numbers of
co m plain ts o n da y 4 were o nly 3 1% (C Q)
and 38 % (SP) of th ose observed on d ay o.
Differences in the resolut ion o f specific co mplaints between the two main treatme nt
groups (i.e. C Q t'. SP) were not statistically
significant, with P-values between 0.2 and
0.98 (d ata no t shown) . F ever ( i.e. an axillary
temperature > 37.5"C) resolved by day 2
among those treated with C Q but not until
da y 3 am ong those treated with SP ( P> 0.05).

Outcomes of th e In-vivo Tests
Of the 40 subjec ts treat ed with CQ for
P. falcipanun, two were lost to follow-up after
day 0 or d ay I of the rapy. Of 22 recurrent,
same-species infection s, four we re exclu ded
from analysis because the day-of-recurrence
P. fa lciparum DNA co uld not be amp lified
for M SP-2 genoryping , leavin g 34 eva luable
infections. T hi rteen (38%) of these 34
co mpleted the test with ou t recurrent parasitaernia, three (9%) developed intercurren t
P. 'l:i'l'ux during the post -therapeutic course,
and the rem aining 18 (5 3%) developed
recurrent P. fakiparum infections during
follow-up . Based on MSP-2 genoryping,
most (14) of the recurrent P. [alcipannn
infections we re identified as recrudescences
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and th e o th er fou r as re-infecti ons. T aking
all of the ide nt ifiab le co n fou ndi ng factors
into co ns idera tion, the ove ra ll cum ulative
incidence of failure of C Q therapy for
un com plicat ed P. [alciparnm was 47 %
Cr able 4).

Un detectable
5

Of th e 87 sub jects treat ed with C Q for
P. -uiuax, nine were lost to follow- up between

day 0 and d ay 2 of therapy. O f 22 recurrent,
sam e-s pecies infections, o ne was excluded
from ana lysis because the correspo nding day-Z
CQ + DCQ co ncent ration was < 30 5 ng /rnl,
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leaving 77 eva lua ble in fectio ns. Forty-two
(5 5%) o f th ese 77 com p leted the test
without rec u rre nt par asit aernia, 12 (1 6 l Yi,)
develo pe d intercurrent P. [ alcipurum (and
co n trib ute d pe rson-time: at risk up to th e d ay
of th at diagn osis) and two (3%1) we re lost to
fo llow-up when aparasitae rnic (one after d ay
7 and th e othe r after d ay 14). The remaining 2 1 subjects (27%) d evelop ed recurrent
P. uiuax at some tim e during follow- up .
Eleven o f the re cu rrent P. ciuax infectio ns
were co nside red to be recru des cent (resistant ),
based on co ncurr ent C Q + DCQ conc entrati ons th at were > 100 ng/m l, The othe r
10 recu rr ent P. vivax infectio ns, a ll of which
oc cu rre d on d ay 28 of follow-up, were
designated as relapses or re- infections becau se
th e co rrespond ing day-of-recurre nce concentrations of C Q + D CQ were < 10 0 nglmJ.
Taking all of th e ide nt ified con fou nd ing
factors into co ns id eration, th e overall cu m ulative incid ence o f failure of C Q th erapy for
un complicated I '. uioax was 18 % (T able 4).
Fifty-four subjects we re treated with SP
for P. fa lciparum infections. O f 17 recurre nt,

same-species infections, four were excluded
from th e analysis because the day-O o r d ayof-rec u rre nc e P. [alciparu m D N A could not
be amplified for MSP-2 genoryping, leaving
50 eval uable infec tions. Twenty-ni ne (58 %)
o f the se 50 completed the test without rec urrent pa rasitae mia, seven (1 4 % ) developed
in terc u rr e n t P. vivax (a n d co n t rib u ted
person-tim e at risk u p to th e da y of tha t
diagnosi s), and one (2%) was lost to followup after d ay -1 . The rem ainin g 13 sub jects
(26%) d evelop ed recurrent P. fa lcipurum at
some time during follow -up . Of these 13,
nine were consid ered recru d escent and four
as new infection s, ba sed on th e results o f
MSP-2 genoryping, The overall cu m ulative
incidence offailure o f SP therapy for uncomplicated P. [alcipa rum was therefore 2 2%
(Ta ble 4).
O f th e six sub jec ts treated with SP for
P. v ivax, no ne was lo st to foll ow-up o r
excluded fro m ana lysis. T wo o f the six
complet ed the test \v·itho ur recu rre n t par asitaem ia bu t the remaining four sub jects pre-

scn ted with recurr en t pa ras itaemia (one eac h
on d ays 7, I I , 18 and 28 ) yield ing a cru de
estima te of risk of SP the rape utic failure of
67'% (Ta ble 4 ) .

Com paris o n b e tw e en the
Micr os copica l a nd peR-based
Diagnoses
The PeR-based am plification was successful for 16 3 of th e 167 su bjects en ro lled sam ples were not avai lab le for amplificatio n
fro m two subjects with pu re P. falc iparum
infecti on and one with a m ixed P. [alcipannnt
P. uiuax infect ion, and no prod uct was
am plified fro m a sample collected from a
subjec t wi th a pure P. oirox infection . All 38
sub jects wh o we re classified as th erapeu tic
failu res (1 5 su bjec ts with 1'. uioax and 23
with 1'. falciparum) provi d ed d ay-o f-failure
samples that were successfully evalua ted by
PCR. When the resu lts fro m th e PCR were
com pared with those of the mi cr oscopical
diagnosis (Table 5), the ove rall sens itivity of
either m ethod , co mpared with the other,
for d et ectin g the ap propriate species with
perfect co nco rda nce was 59 (%.

DISC USSION
The presen t results ind icat e th at resist an ce
to C Q in both P. [alciparum and P. uicax,
and to 51' in P. fal ciparnm, is co mmon in
the Menor eh H ills of Centra l Java . Alm ost
on e in every two (4 7%) of the P. [a kipurnm
infections in thi s are a is res ista n t to C Q,
2 2 % of th e P. [ alcipannn infec tions ar c
resi stant to SP, and 18% of the P. vivax
are resistant to C Q . T hese findings corro borate those of sim ilar stud ies elsewhere in
Ind ones ia (S mrkovski ct ai., 1983; Baird el ol.,
1991 , 1997b; FryauIf er al., 199 7, 1998a , b)
and su pport th e use of SP as the first-line
th erapeutic choice again st P. [alcipa runr
m alari a in Java and the rete n tio n of CQ as
the first-line treatment for P. riuax m alari a.
H owever, {his approach is serio usly limited
where spec ies determination may be unreli able
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N o. (If positive samples in the PeR-based assay
Day of th era peutic failu re
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0
2
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• Concorda nt resu lt.

or u navailable, since m isidentificati on o f a
P. [alciparum or mixed P. faldpanuntl>: oiu ax
infection as a p u re infectio n wit h 1'. v ivax
would the n ofte n resul t in ineffec tive therapy.
A common first-line therapy effective against
both P. fakiparum and P. uiuax need s to
be iden tified . Such a trea tmen t wo uld serve
a vita l strategic role in reg ainin g co n tro l of
ma la ria in Java .
The in-vivo test used in th e present stu dy
represents a modification of the standa rd,
28-day, 'extend ed ' field test (W H O , 19 73),
the most importa nt changes being in th e
recruitment criteria and follow- up . The proced u res rec o m mended by the Wo rld H ealth
Organizati on (\V HO) we re not designed for
well -equipped research teams on temporary
assignment but for the staff of ru ral clinic s,
using routinely available reso urces (W HO,
197 3). The W HO' s protocol call s for passive
m ethods of subject identification and followup. In contrast, a re searc h team o ften
possesses both the means and motivation
(in terms o f the economic usc of effort
and inves te d time and reso urces) for active
recruitm en t and follow -up. As the current
Mcnorch-Hills epidemic began, in an area
wh ere the re had been no ro u tine passive
su rveilla nce of drug efficacy , the local
he alth authori ties u rgen tly required definitive
information on the th erapeut ic efficacy of
the an tim alarial d rugs avai lab le to th em . A
research team - that co uld ob tai n th e
required informa tio n with a mi n ima l inves t-

me n t in time an d resou rces - was therefore
dis pa tc he d fro m th e U .S. N aval Medical
Research Un it in Jak art a.
The WHO 's method may be co nfo unded
by factors such as drug absorption , diagnostic
sens itivity, and an inabi lity to d isti ng uis h
recrudescence from re-infection an d relap se.
In th e p rese n t study, the issue of drug
abso rption wa s specifica lly add re sse d b y
employi ng HPLC to d eterm ine b lood conccnr rations of C Q , D C Q , su lfadoxine and
pyrimethamine. Confirmation of the prese nce ,
at the time of rec u rrent parasitaernia, of
C Q + DCQ co ncentra tions that exceeded
the mini mal effective concen tration (l\l E C)
provides d efinitive evidence o f re sistance.
The MEC of C Q agains t (C Q -sensitive)
P. vivax has been estimated to be 15 m glml
plasma (ro ughly 120 ng/rnl whole blood;
Berline r ec al., 1948), 90 ng/ml wh ole blood
(Ro mbo et al., 1986) and , in Indonesia,
100 ng/rnl whole blood (Baird ct al., 1997 a) .
Although the M E C for SP is not kn own with
certainty, concentrations of sulfad oxinc and
pyrimethamine were m easured on the d ay
of recurrence in those treated with SP in th e
present stud y, to assess th e likel ihood that
ab sorption of th ese drugs had been nonna!.
Rased on elim inat ion half-lives of about 180 h
for su lfadoxine and 90 h for pyrimethamine
(Weid ekam m et al., 1982), five of the six
su bjects who failed SP treatmen t had drug
co ncentrations consisten t with no rmal absorption . Alth ough inter-ind ividual varia tio ns in
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the pla sm a concentrations of su lfad oxine
and pyrimethamine may be wide, the drug
concen tra tions measured during the recurrent
infections in the pre sent stu d y were comparable with the value s reponed by others
(Sarikab u thi <1 al., 198 8; H cllgrcn el al.,
199 0) . 11,e abi lity to m easure drug concentra tions in subjects may p revent inappropriate
inclusion of those with inadequate ab sorption as treatment failure s, thereby minimizing
the over-estimation o f treatment failure.
There is d earl y a ne ed for further inve stigations of th e MEC for su lfadoxine and
pyrimethamine.
The W HO's method (W H O, 1973 )
ma y also be confounded by low diagnost ic
sens itivity and the inability to di stinguish
recrud escence from re-infection and relapse .
In the present stud y, relatively so p h istica ted
laborato ry tests were cond ucted [0 sup port
the cla ssification of infections as resistant or
sens itive. These inclu d ed the PCR-based
detection of infectio n, an d the 1\ 15 1'-2 ba sed genoryping of parasites, [0 di stinguish
re-infecti on from recrudescence in th ose
infe cted with P. [alciparum. Sev eral rep orts
sup po rt thi s application (Babiker <1 al.• 1994 ;
Ohrt et al., 199 7; Bro ckman er al. , 199 9),
wh ich allows a m ore accura te estimat e of
the risk of th erapeutic failu re becau se of
resista nce than would o therwise be possible.
The P CR-based di agn osis of malari a in
clin ica l se ttings presents many uncertainties.
The sensitivity and specificity of such diagnosis
are difficult to estimate against a microsco pica l stan da rd that is almos t cert ain ly
less ac curate . T he freq uencies of fa lsepositive and false- negative diagnoses remain
u n known . M o reover, sta n d ard protocols and
sets o f reagents ma nufactured for clinical use
are no t yet available. The results o f so me
stu d ies in d ica te a poor co rre latio n between
th e results of a PCR-based ass ay and of
microscopy (Gaye r!l ul. , 1999; Tham et al.,
199 9) . Cryptic P. falciparum in fecti ons m ay
often accom pa ny infection s d iagnosed as
pure P. 1!i'1.'ax and only become detectable by
microscopy after CQ treatment (Mason et al.,
200 1; M ayx a y et al., 200 1; Siripoon a al.,

2002). In the- pre sent stu dy, P. fukipun nn was
so me tim es d etected, after C Q treatment, in
sub jects wh o ap pea red (by m icro scopy) to
have h ad pure P. cieax infection s at enrollment. H owever, thi s occurred primari ly in
su bjects who were found to have h ad the
ss rRN A o f both P. [alciparum and 1'. vivax
in their blo od at en ro llm en t, indicating
th at they had (m icrosco p ically) cryp tic
P. [alcipannn at th at time . The clinical
significa nce of d isco rdan t P CRJmicroscop y
diagn oses remains un clear, an d the possib ility th at the re are false-posi tives among
the PCR res u lts, for which n o proba bility
h as been estimate d, must be co nside red . In
the present study, therefor e, use of p eR
was limited to affirming th e microscopical
d iagnoses, and a positive PCR result was not
co ns ide red evidence of parasit acmia unl ess
parusitacmia was d etect ed , in the corresponding bloodsrnear, by at least one
mi croscopist.
The WHO's p ro tocol requires a minimum parasit aem ia of I000 para sites/ul for
1'. fulciparum, Alth ough the majority of sym pto matic malaria cas es re po n ing to clinics
have pa rasitae rnias above th is th resh old, most
people fo un d to have ma larial infec tio ns
durin g active case d etecti on typically h ave
co nside rably lower parasite cou nts. In the
presen t st udy, for exa m ple , th e median
parasite co u n t for P. [alciparum at en roll ment was only 840/pl. Excl udi ng sub jects
with pa ras ite de ns ities below the \X'HO's
thresho ld not on ly compromi ses the efficiency
of recruitment but may also introduce <1
profound sam ple bias. If th ose with parasitae mias of at least 1000 para sites/ul
comprise on ly a minori ty o f all th ose with
parasit acrn ia, they clea rly d o n ot rep resen t a
su ita ble, re p resen ta tive group for estimating
th e community-wide risk of th era pe u tic
failu re.
T he presen t es timates of the risk of therapeu tic failure attrib utab le to resistance arc
th e resul ts of a syste matic effo rt to mini m ize
class ification errors, by usin g the relatively
so phis tica ted lab or at ory tec h niq ues available
to th e research tea m. The es tima tes indi cat e
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an inadeq uate the rapeu tic respo nse to C Q,
and a modestly efficac ious res po nse to SP
among the P. fo lcipannn in fect ion s in vest igated. A combination of C Q and SP recentl y
showed > 90 %, efficacy again st un complicated P. [alcinannn mala ria in the Ce n tral
province of j ava (J . K . Baird, un pub!. obs.),
and this combination may rep resent the
mo st appropriate treatm ent un til o ther combined therapies arc evaluated and licen sed
in In donesia. Resistance to CQ by P. uiuax
occurred in 18 % of th e infections evaluated
in Purworcjo ( p resen t st ud y). This represen ts th e first co nfirmation of C Q -resista n t
P. vivax ma laria on the isla nd of Java . The
m ust important p roblem with m ain tain ing
C Q as first -line therapy for P. uiuas malaria
is not th e 20 % risk of therapeu tic failure b ut
rather the rnuch higher risk o f using C Q
against misd iagnosed P. fatcipanon m ala ria
and th e predictably po or o utcome in that
even t. A safe and effe ctive trea tmen t for both
P. falc ipa runt and P. ciuax malaria is the refore vitally needed in areas such as the
M cn or eh Hill s of Central j ava .
The asse rtions he rein
are the views of the authors and d o not
reflect official po licy of the U .S. D epart ment
of the Navy or th e U .S. Department of
Defense. The G lobal Emerging In fection s
Surveillance program of the U .S. D epart ment o f Defense sup po rted th is work. The
authors grat efully acknowledge the advice and
ass ista nc e of many officers of the Repu blic
of Ind onesia M in istry of H ealth , especially
Drs A. S . Suparrnanto and Ingerani of
the Na tional Institu te of H ealth Research
in Jakarta. T hi s work wo uld not hav e been
po ssib le without th e extremely hard work
co n tribu ted by Suradi, Sunardi, P um o rn o,
A. Rahmat , I. Elyazar and WI . Kania.
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